Erschienen in:
20.08.2019 | Author Correction
Correction to: Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy
verfasst von:
A. Passaro, P. Mancuso, S. Gandini, G. Spitaleri, V. Labanca, E. Guerini-Rocco, M. Barberis, C. Catania, E. Del Signore, F. de Marinis, F. Bertolini
Erschienen in:
Clinical and Translational Oncology
|
Ausgabe 4/2020
Einloggen, um Zugang zu erhalten
Excerpt
Acknowledgements section was missing in the original published version. The Acknowledgement section read as follows: …